In three out of the four relapses, CD19 expression remained negative.149 Aftertreatment with CD19/BCMA dual-targeting Fastcar-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (R/R B-NHL), the 3-month overall response rate was 100%, with 77.8% (7/9) reaching CR and no relapse was noted within the follow-up period.150. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.